NDAINTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
BORTEZOMIB (bortezomib) by Medica Corp is proteasome inhibitors [moa]. First approved in 2024.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bortezomib is a proteasome inhibitor small molecule approved in August 2024 for intravenous and subcutaneous administration. It works by inhibiting the 26S proteasome, preventing degradation of proteins that regulate cell cycle and apoptosis, inducing cancer cell death. The drug is indicated for hematologic malignancies, particularly multiple myeloma and certain lymphomas.
Growth
Product is in early growth phase post-approval with moderate competitive pressure (30%), suggesting active team expansion and commercial opportunity.
Mechanism of Action
Proteasome Inhibitors
Pharmacologic Class:
Proteasome Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
Started Oct 2026
20 enrolled
Multiple Myeloma
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma
Started Aug 2026
120 enrolled
Multiple Myeloma
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Started Jul 2026
500 enrolled
Multiple Myeloma
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Started Jun 2026
720 enrolled
Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Started Mar 2026
60 enrolled
Amyloidosis
Worked on BORTEZOMIB at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.